SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (25656)9/22/1998 9:34:00 PM
From: jayhawk969  Respond to of 32384
 
Henry,

I have the same comment from IR.

Also from page 71 of the Seragen Proxy Statement/Prospectus:

Lilly Fill/Finish of product. Lilly agreed to perform the final formulation, sterile filling, packaging and labeling of the bulk DAB---IL-2 supplied by Seragen or Ligand(the Fill/Finish") for a period of five years after the earlier of the date of first commercial sale of DAB---IL-2 or the Closing.

J.D.



To: Henry Niman who wrote (25656)9/22/1998 11:36:00 PM
From: growthvalue  Read Replies (1) | Respond to of 32384
 
"JD, LGND IR told me that if the manufacturing facility was not profitable, they would sell it (I think within a year)."

It's interesting that while LGND is willing to "limit their options" in the event that the manufacturing facilities are unprofitable, they're not willing to do the same regarding their financing options for the Seragen transaction in the event that LGND's stock price is low.

GV


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News